A PYMNTS Company

Mexico: Regulator Investigates pharmaceutical market concentration

By  |  January 11, 2018
Mexico: Regulator Investigates pharmaceutical market concentration

According to a press release by COFECE, Mexico’s antitrust regulator, they have evidence suggesting the existence of an unlawful concentration among companies in the market for the distribution and wholesale of pharmaceutical, personal care and beauty products.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Unlawful concentrations obstruct, diminish, harm or impede competition by increasing an economic agent’s substantial market power; they displace, impose barriers to market entry or impede free market access or access to other competitors’ essential facilities, and/or facilitate that concentrating parties incur in monopolistic practices that harm consumers.

    If a concentration is determined unlawful, COFECE’s Board of Commissioners may impose sanctions.

    Full Content: COFECE Release

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.